188 related articles for article (PubMed ID: 23344731)
1. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.
Watson AM; Olukman M; Koulis C; Tu Y; Samijono D; Yuen D; Lee C; Behm DJ; Cooper ME; Jandeleit-Dahm KA; Calkin AC; Allen TJ
Diabetologia; 2013 May; 56(5):1155-65. PubMed ID: 23344731
[TBL] [Abstract][Full Text] [Related]
2. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet.
Papadopoulos P; Bousette N; Al-Ramli W; You Z; Behm DJ; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
Atherosclerosis; 2009 Jun; 204(2):395-404. PubMed ID: 19111831
[TBL] [Abstract][Full Text] [Related]
3. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.
Liu F; Sahoo R; Ge X; Wu L; Ghosh P; Qin X; Halperin JA
J Diabetes Complications; 2017 Feb; 31(2):311-317. PubMed ID: 27729184
[TBL] [Abstract][Full Text] [Related]
5. Urotensin II receptor knockout mice on an ApoE knockout background fed a high-fat diet exhibit an enhanced hyperlipidemic and atherosclerotic phenotype.
Bousette N; D'Orleans-Juste P; Kiss RS; You Z; Genest J; Al-Ramli W; Qureshi ST; Gramolini A; Behm D; Ohlstein EH; Harrison SM; Douglas SA; Giaid A
Circ Res; 2009 Sep; 105(7):686-95, 19 p following 695. PubMed ID: 19696412
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory vasostatin-2 attenuates atherosclerosis in ApoE
Xiong W; Wang X; Dai D; Zhang B; Lu L; Tao R
Thromb Haemost; 2017 Jan; 117(2):401-414. PubMed ID: 27831589
[TBL] [Abstract][Full Text] [Related]
7. Urotensin II and urantide exert opposite effects on the cellular components of atherosclerotic plaque in hypercholesterolemic rabbits.
Yu QQ; Cheng DX; Xu LR; Li YK; Zheng XY; Liu Y; Li YF; Liu HL; Bai L; Wang R; Fan JL; Liu EQ; Zhao SH
Acta Pharmacol Sin; 2020 Apr; 41(4):546-553. PubMed ID: 31685976
[TBL] [Abstract][Full Text] [Related]
8. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lu Z; Zhang X; Li Y; Jin J; Huang Y
J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
[TBL] [Abstract][Full Text] [Related]
9. Genetic and pharmacological manipulation of urotensin II ameliorate the metabolic and atherosclerosis sequalae in mice.
You Z; Genest J; Barrette PO; Hafiane A; Behm DJ; D'Orleans-Juste P; Schwertani AG
Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):1809-16. PubMed ID: 22723440
[TBL] [Abstract][Full Text] [Related]
10. Potent Vasoconstrictor Kisspeptin-10 Induces Atherosclerotic Plaque Progression and Instability: Reversal by its Receptor GPR54 Antagonist.
Sato K; Shirai R; Hontani M; Shinooka R; Hasegawa A; Kichise T; Yamashita T; Yoshizawa H; Watanabe R; Matsuyama TA; Ishibashi-Ueda H; Koba S; Kobayashi Y; Hirano T; Watanabe T
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411243
[TBL] [Abstract][Full Text] [Related]
11. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.
Rakowski E; Hassan GS; Dhanak D; Ohlstein EH; Douglas SA; Giaid A
J Mol Cell Cardiol; 2005 Nov; 39(5):785-91. PubMed ID: 16171813
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma urotensin II levels in patients with diabetes mellitus.
Totsune K; Takahashi K; Arihara Z; Sone M; Ito S; Murakami O
Clin Sci (Lond); 2003 Jan; 104(1):1-5. PubMed ID: 12519081
[TBL] [Abstract][Full Text] [Related]
13. Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Wang T; Xie L; Bi H; Li Y; Li Y; Zhao J
Eur J Pharmacol; 2021 Jul; 902():174037. PubMed ID: 33891969
[TBL] [Abstract][Full Text] [Related]
14. Age-Related Reduction of Contractile Responses to Urotensin II Is Seen in Aortas from Wistar Rats but Not from Type 2 Diabetic Goto-Kakizaki Rats.
Matsumoto T; Watanabe S; Kobayashi S; Ando M; Taguchi K; Kobayashi T
Rejuvenation Res; 2017 Apr; 20(2):134-145. PubMed ID: 27841739
[TBL] [Abstract][Full Text] [Related]
15. Urotensin II Enhances Advanced Aortic Atherosclerosis Formation and Delays Plaque Regression in Hyperlipidemic Rabbits.
Yu Q; Wei P; Xu L; Xia C; Li Y; Liu H; Song X; Tian K; Fu W; Wang R; Wang W; Bai L; Fan J; Liu E; Zhao S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835230
[TBL] [Abstract][Full Text] [Related]
16. Novel insights into the role of urotensin II in cardiovascular disease.
Pereira-Castro J; Brás-Silva C; Fontes-Sousa AP
Drug Discov Today; 2019 Nov; 24(11):2170-2180. PubMed ID: 31430542
[TBL] [Abstract][Full Text] [Related]
17. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.
Bousette N; Pottinger J; Ramli W; Ohlstein EH; Dhanak D; Douglas SA; Giaid A
Peptides; 2006 Nov; 27(11):2919-26. PubMed ID: 16919371
[TBL] [Abstract][Full Text] [Related]
18. Endothelium-restricted endothelin-1 overexpression in type 1 diabetes worsens atherosclerosis and immune cell infiltration via NOX1.
Ouerd S; Idris-Khodja N; Trindade M; Ferreira NS; Berillo O; Coelho SC; Neves MF; Jandeleit-Dahm KA; Paradis P; Schiffrin EL
Cardiovasc Res; 2021 Mar; 117(4):1144-1153. PubMed ID: 32533834
[TBL] [Abstract][Full Text] [Related]
19. Ursolic acid protects diabetic mice against monocyte dysfunction and accelerated atherosclerosis.
Ullevig SL; Zhao Q; Zamora D; Asmis R
Atherosclerosis; 2011 Dec; 219(2):409-16. PubMed ID: 21752377
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes.
Koïtka A; Cao Z; Koh P; Watson AM; Sourris KC; Loufrani L; Soro-Paavonen A; Walther T; Woollard KJ; Jandeleit-Dahm KA; Cooper ME; Allen TJ
Diabetologia; 2010 Mar; 53(3):584-92. PubMed ID: 19957160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
